Mabwell To Roll Out Denosumab Biosimilars Across Pakistan And Egypt

Xgeva Biosimilar Candidate Still Pending Approval In China

01 Aug 2023

Chinese biopharma Mabwell has formed licensing agreements in Pakistan and Egypt to roll out its denosumab biosimilars.

Map of Asia and north east Africa, featuring China, Pakistan and Egypt — Mabwell has partnered with Searle in Pakistan and an unnamed business partner in Egypt • Source: Shutterstock

Chinese biopharma Mabwell has entered into licensing agreements with Pakistani pharmaceutical company Searle and an unnamed business partner in Egypt for its denosumab biosimilars Mailishu and 9MW0321.

Searle will manufacture, register and market the drugs in Pakistan, while in Egypt the anonymous partner will hold exclusive sales rights while Mabwell will be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Adalvo And Gedeon Richter Join Forces On Semaglutide

06 May 2025

• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.